IRIS
BATTISTA, TERESA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.018
EU - Europa 1.830
NA - Nord America 1.587
SA - Sud America 369
AF - Africa 82
OC - Oceania 4
Totale 6.890
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.511
SG - Singapore 1.304
RU - Federazione Russa 875
CN - Cina 733
DE - Germania 546
VN - Vietnam 407
BR - Brasile 309
HK - Hong Kong 173
IN - India 126
IT - Italia 98
KR - Corea 95
FI - Finlandia 81
FR - Francia 67
JP - Giappone 48
GB - Regno Unito 43
CA - Canada 34
AR - Argentina 30
CI - Costa d'Avorio 26
ZA - Sudafrica 24
MX - Messico 23
BD - Bangladesh 20
NL - Olanda 18
IQ - Iraq 17
PK - Pakistan 17
UA - Ucraina 16
PL - Polonia 15
ES - Italia 14
ID - Indonesia 12
EC - Ecuador 11
AT - Austria 10
PH - Filippine 10
MA - Marocco 8
TH - Thailandia 8
KE - Kenya 7
SE - Svezia 7
TR - Turchia 7
EG - Egitto 6
IE - Irlanda 6
JO - Giordania 6
LT - Lituania 6
TW - Taiwan 6
IL - Israele 5
PY - Paraguay 5
RS - Serbia 5
TN - Tunisia 4
VE - Venezuela 4
AZ - Azerbaigian 3
CL - Cile 3
CO - Colombia 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
JM - Giamaica 3
SA - Arabia Saudita 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BE - Belgio 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
HR - Croazia 2
KH - Cambogia 2
LB - Libano 2
OM - Oman 2
PE - Perù 2
PR - Porto Rico 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
EE - Estonia 1
GA - Gabon 1
GN - Guinea 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HT - Haiti 1
HU - Ungheria 1
KG - Kirghizistan 1
KW - Kuwait 1
LC - Santa Lucia 1
LV - Lettonia 1
MD - Moldavia 1
MQ - Martinica 1
MR - Mauritania 1
MY - Malesia 1
NC - Nuova Caledonia 1
NO - Norvegia 1
PA - Panama 1
PG - Papua Nuova Guinea 1
QA - Qatar 1
RO - Romania 1
SY - Repubblica araba siriana 1
Totale 6.889
Salva come PNG Salva come JPEG
Città #
Singapore 690
Hefei 386
San Jose 340
Moscow 228
Hong Kong 166
Santa Clara 161
Ashburn 149
Ho Chi Minh City 127
Beijing 124
Munich 113
Krefeld 111
Hanoi 92
Seoul 83
Kochi 82
Chandler 74
Lauterbourg 55
Helsinki 52
Los Angeles 52
Tokyo 44
The Dalles 43
Bad Bellingen 42
New York 36
São Paulo 35
Redondo Beach 28
Dallas 27
Chicago 24
Buffalo 22
Da Nang 22
Boardman 19
Boston 16
Haiphong 15
Lappeenranta 14
Milan 14
Rome 14
Chennai 13
Frankfurt am Main 13
Houston 13
Rio de Janeiro 13
Warsaw 13
Biên Hòa 12
Naples 12
Seattle 12
London 11
Mexico City 11
Montreal 10
Orem 10
Pune 10
Falkenstein 9
Brooklyn 7
Council Bluffs 7
Denver 7
Lahore 7
Phoenix 7
Porto Alegre 7
Rochdale 7
Toronto 7
Xi'an 7
Amman 6
Atlanta 6
Belo Horizonte 6
Campinas 6
Dublin 6
Jyväskylä 6
Manchester 6
Nairobi 6
Poplar 6
Ribeirão Preto 6
San Francisco 6
Stockholm 6
Turku 6
Amsterdam 5
Bắc Giang 5
Curitiba 5
Erbil 5
Guangzhou 5
Johannesburg 5
Karlsruhe 5
Nuremberg 5
Campo Grande 4
Can Tho 4
Düsseldorf 4
Kingston 4
Paris 4
Phủ Lý 4
Quito 4
Salvador 4
Santo André 4
Turin 4
Zhengzhou 4
Ankara 3
Bad Durrheim 3
Baghdad 3
Baku 3
Basra 3
Belém 3
Cairo 3
Calgary 3
Caxias do Sul 3
Ciudad del Este 3
Edinburgh 3
Totale 3.920
Salva come PNG Salva come JPEG
Nome #
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study 394
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis 282
Alopecia Areata after COVID-19 Vaccines 158
Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study 157
Management of Psoriasis Patients with Serious Infectious Diseases 136
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience 132
Real-world practice indirect comparison between guselkumab, risankizumab and tildrakizumab: results from an Italian 28-week retrospective study 132
Comment on ‘Anogenital dermatology: challenges in the digital era’ 131
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients 129
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients 128
Treatment of hereditary hypotrichosis simplex of the scalp with oral minoxidil and growth factors 124
The impact of COVID ‐19 infection on psoriatic patients treated with biologics: an Italian experience 124
An uncommon case of lichen spinulosus induced by dupilumab in a patient treated for bronchial asthma 124
Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature 123
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature 123
COVID-19 and cutaneous manifestations: A review of the published literature 120
Leg paralysis after photodynamic therapy for Lymphomatoid Papulosis: a case report 119
Risk Factors for Psoriasis Flares: A Narrative Review 118
Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real‐life study 118
Acrodermatitis continua of Hallopeau successfully treated with ixekizumab: A case report 117
Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis 116
Generalized versus localized vitiligo after ixekizumab: May previous treatment affect the clinical presentation? 115
Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19 111
Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis 111
Immune response to Covid‐19 mRNA vaccination in psoriasis patients undergoing treatment with biologics 109
The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials 108
Epidermolysis bullosa: new insights for the future 108
Hidradenitis Suppurativa Cancer Risk: A Review of the Literature 106
Reply to “Nail psoriasis: a rare mRNA COVID ‐19 vaccine reaction” by Lamberti A et al 105
Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a psoriasis patient. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab" 105
Comment on ‘Pityriasis rubra pilaris-like eruption following mRNA COVID-19 vaccine’ 104
A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab 104
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge 103
Pemphigus Vulgaris and COVID-19 vaccination: Management and Treatment 101
Guselkumab-induced vitiligo in a patient with psoriatic arthritis 100
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review 99
Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future? 99
The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature 98
Comment on: "Associations between hidradenitis suppurativa and dermatological conditions in adults: A national cross-sectional study by Brown et al." 97
Dupilumab for the treatment of adult atopic dermatitis in special populations 95
Comment on 'Morphoea following COVID-19 vaccination' 95
Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study 94
COVID-19 vaccination and inflammatory skin diseases 94
Atypical case of cutaneous Rosai-Dorfman disease 92
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa' 89
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review 87
Hidradenitis Suppurativa in Elderly Patients: Clinical and Therapeutical Outcomes—A Review of the Literature 85
Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study 85
Reply to ‘Effectiveness, safety and drug survival of oral roflumilast for hidradenitis suppurativa’ by Holgersen et al 84
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report 81
Viral Reactivation Following COVID-19 Vaccination: a review of the current literature 79
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data 78
Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa” 72
Bullous pemphigoid and COVID ‐19 vaccination: management and treatment Reply to ‘Bullous pemphigoid in a young male after COVID ‐19 mRNA vaccine: a report and brief literature review’ by Pauluzzi et al 68
Reply to “Dalbavancin for the treatment of severe hidradenitis suppurativa” 66
Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study 65
Allergic contact dermatitis to petrolatum: An unknown for patch testing 61
Comment on ‘Eosinophilic pustular folliculitis developing at the site of COVID-19 vaccination’ 61
Advancing Dermatology: Embracing the Power of Artificial Intelligence 60
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report 60
Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association 59
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments 57
Severe Paradoxical Scalp Psoriasis Induced by Bimekizumab in a Young Multifailure Hidradenitis Suppurativa Patient 51
Comment on ‘Onset of epidermolysis bullosa acquisita under therapy with ustekinumab for the treatment of Crohn disease’ 51
Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era? 51
The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study 50
Totale 6.958
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.996
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20229 0 0 0 0 0 0 0 1 0 1 2 5
2022/2023284 4 16 3 15 35 29 13 40 37 18 33 41
2023/2024657 11 41 49 22 13 28 10 50 316 16 60 41
2024/20252.199 77 92 15 12 85 171 221 176 150 263 789 148
2025/20263.809 414 645 424 426 565 158 333 223 355 181 85 0
Totale 6.958